Central Trust Company’s Alaunos Therapeutics TCRT Stock Holding History

Central Trust Company’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1	Closed	-$19	–	1452
2024 Q1	$19	Buy	+1	New	+$20	﹤0.01%	1369
2018 Q4	–	Sell	-3	Closed	-$2K	–	1233
2018 Q3	$2K	Hold	3	–	–	﹤0.01%	1187
2018 Q2	$2K	Hold	3	–	–	﹤0.01%	1198
2018 Q1	$2K	Hold	3	–	–	﹤0.01%	1211
2017 Q4	$2K	Sell	3 -20	-87%	-$14.4K	﹤0.01%	1206
2017 Q3	$21K	Hold	23	–	–	﹤0.01%	830
2017 Q2	$22K	Hold	23	–	–	﹤0.01%	829
2017 Q1	$22K	Hold	23	–	–	﹤0.01%	874
2016 Q4	$19K	Hold	23	–	–	﹤0.01%	899
2016 Q3	$20K	Hold	23	–	–	﹤0.01%	841
2016 Q2	$19K	Hold	23	–	–	﹤0.01%	869
2016 Q1	$26K	Hold	23	–	–	﹤0.01%	814
2015 Q4	$29K	Hold	23	–	–	﹤0.01%	782
2015 Q3	$32K	Buy	23 +10	+77%	+$16.5K	﹤0.01%	720
2015 Q2	$24K	Hold	13	–	–	﹤0.01%	818
2015 Q1	$22K	Buy	13 +3	+30%	+$4.45K	﹤0.01%	795
2014 Q4	$8K	Hold	10	–	–	﹤0.01%	1018
2014 Q3	$4K	Hold	10	–	–	﹤0.01%	1099
2014 Q2	$6K	Hold	10	–	–	﹤0.01%	1039
2014 Q1	$7K	Buy	10 +3	+43%	+$2.01K	﹤0.01%	1016
2013 Q4	$4K	Buy	+7	New	+$4.17K	﹤0.01%	1061

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Central Trust Company's TCRT Position: Q2 2024 in Review

Central Trust Company sold out of Alaunos Therapeutics (TCRT) in Q2 2024, closing a stake of 1 share — an estimated $19 sold.

Central Trust Company first reported a position in TCRT in Q4 2013 and held it in 21 quarters. The position peaked at $32K in Q3 2015. 50 funds tracked by Wall St. Rank hold TCRT as of Q2 2024.

Central Trust Company reported no remaining Alaunos Therapeutics position as of Q2 2024 after selling out during the quarter.
Central Trust Company sold 1 Alaunos Therapeutics share in Q2 2024, an estimated $19.
Central Trust Company first reported a position in Alaunos Therapeutics in Q4 2013 and held it in 21 quarters.
Central Trust Company's Alaunos Therapeutics position peaked at $32K in Q3 2015.
50 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2024.

Based on Central Trust Company's 13F filing for Q2 2024, filed 5 Aug 2024.